Randomized phase III trial of cisplatin, epirubicin, leucovorin, 5-fluorouracil (PELF) combination versus 5-fluorouracil alone as adjuvant chemotherapy in curative resected stage III gastric cancer.
OBJECTIVE
The combination of cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) administration, as adjuvant chemotherapy after curative resection for gastric cancer, was compared with 5-fluorouracil (5-FU) administration alone. This paper reports the results of a prospective randomized comparison of the two regimens, PELF and 5-FU.


METHODS
From August 1996 to July 1999, 54 patients were selected subsequent to being diagnosed with stage III cancer after a curative resection for gastric cancer. The patients were stratified according to stage IIIA/IIIB and subtotal/total gastrectomy, and then they were randomized into each treatment group, i.e. the PELF or 5-FU alone groups.


RESULTS
54 assessable patients were enrolled in this study: 28 received PELF and 26 received 5-FU alone. 12 patients relapsed in each group and the median follow-up duration was 42 months (range: 10 approximately 77 months). The overall survival rate and disease-free survival rate (DFS) were not significantly different between two groups, (5-year survival of PELF vs. 5-FU: 57% vs. 64%, 5-year DFS: 54% vs. 51%). The PELF combination was more toxic in terms of anemia, anorexia, nausea and diarrhea than the 5-FU.


CONCLUSIONS
This study showed that the PELF combination, as an adjuvant therapy for gastric cancer after a curative resection, was a less effective treatment, and it had more toxic effects than the 5-FU.
Lee
Jae Jin
JJ
Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea.
Kim
Si-Young
SY
Shin
Im Sik
IS
Cho
Kyung Sam
KS
Joo
Hoong-Zae
HZ
Yoon
Choong
C
Kim
Yoon Wha
YW
Yoon
Hwi Joong
HJ
World J Surg. 1977 Mar;2(1):213-21
868069
J Surg Oncol. 1994 Dec;57(4):239-42
7990479
J Clin Oncol. 1993 Aug;11(8):1441-7
8336183
Ann Oncol. 1991 Mar;2(3):229-30
2043494
Acta Oncol. 2001;40(2-3):309-26
11441938
J Clin Oncol. 1990 Aug;8(8):1362-9
2199622
Br J Cancer. 1996 Feb;73(4):549-52
8595173
Cancer. 1974 Nov;34(5):1576-86
4279136
Am J Clin Oncol. 1999 Dec;22(6):580-6
10597742
World J Surg. 1984 Jun;8(3):308-14
6464487
J Clin Oncol. 1994 Dec;12(12):2687-93
7989945
Ann Surg Oncol. 2000 Apr;7(3):210-7
10791852
Ann Oncol. 1997 Feb;8(2):163-8
9093725
J Clin Oncol. 1999 Dec;17(12):3810-5
10577853
Eur J Cancer. 1999 Jul;35(7):1059-64
10533448
Ann Surg Oncol. 1995 Nov;2(6):488-94
8591078
Eur J Cancer. 1993;29A(3):340-2
8398330
N Engl J Med. 1999 Mar 25;340(12):908-14
10089184
J Clin Oncol. 1999 Jan;17(1):319-23
10458249
Int Surg. 2000 Jul-Sep;85(3):209-15
11324997